Citations

Clear

426 citation(s) found for "ST, Reza".

Breast arterial calcifications on mammography and risk of stroke: a systematic review and meta-analysis
Ghozy, Sherief, Ali, Mohamed Ahmed, Sadiq, Muhayman, Pakzamir, Pedram, Fattahi, Mohammad Reza, Borkar, Rachana R. , Kadirvel, Ramanathan , Conners, Amy Lynn , Kallmes, David F., Ghozy, Sherief , Jazayeri, Seyed Behnam , Sadiq, Muhayman, Fattahi, Mohammad Reza, Ghadery, Abdolkarim Haji , Dmytriw, Adam A. , Kallmes, David F.

Mayo Clinic

Frontiers in Neurology | February 5, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fneur.2026.1716747 | PMID 41725727 Get It

Background Breast arterial calcifications (BAC) are commonly observed as an incidental finding on screening mammography and have been linked to cardiovascular disease. Whether BAC is independently associated with stroke risk remains uncertain. Methods We conducted a systematic review and meta-analysis in accordance with PRISMA 2020 guidelines. PubMed, Embase, and Scopus were searched from inception to May 2024 for cohort studies evaluating the association between BAC and stroke. Eligible studies included women undergoing mammography with documented BAC status and subsequent stroke outcomes. Data on patient characteristics and vascular risk factors were extracted. Study quality was appraised using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist. Random-effects meta-analyses with restricted maximum likelihood (REML) estimation were performed to pool risk ratios (RRs) and mean differences (MDs). Heterogeneity was assessed with the I 2 statistic, and publication bias with Egger’s test. Results Ten cohort studies including 52,413 women were analyzed. The presence of BAC was associated with more than a twofold increased risk of stroke (RR 2.09, 95% CI 1.58–2.75; I 2 = 64.4%). This association persisted after adjustment for age, diabetes, hyperlipidemia, and menopausal status. Compared with BAC-negative women, those with BAC were significantly older (MD 7.07 years, 95% CI 5.44–8.70) and more frequently hypertensive (RR 1.48, 95% CI 1.23–1.78), diabetic (RR 1.67, 95% CI 1.38–2.02), hyperlipidemic (RR 1.27, 95% CI 1.07–1.51), and postmenopausal (RR 1.26, 95% CI 1.00–1.59). Interestingly, BAC was less common among smokers (RR 0.62, 95% CI 0.45–0.86). Egger’s test showed no evidence of publication bias ( p = 0.143). Conclusion BAC detected on screening mammography is independently associated with an increased risk of stroke, even after accounting for traditional risk factors. These findings support BAC as a promising, underutilized imaging biomarker of cerebrovascular risk in women and highlight the need for standardized reporting and prospective validation.
The diagnostic and prognostic value of high-sensitivity troponin T for cardiovascular outcomes in patients receiving immune checkpoint inhibitor therapy
Farina, J F, Awad, K, Kanaan, C N, Tagle-Cornell, C, Novais, B S, Koepke, L M, Kenyon, C R, Larsen, C M, Narayanasamy, H, Tamarappoo, B T, Lee, K L, Herrmann, J, Arsanjani, R A, Ayoub, C A, Pereyra, M, Awad, Kamal , Kanaan, Christopher , Tagle‐Cornell, Cecilia, Novais, Barbara S., Koepke, Laura, Kenyon, Courtney , Larsen, Carolyn , Narayanasamy, Hemalatha , Tamarappoo, B., Herrmann, Joerg , Arsanjani, Reza

Mayo Clinic

European Heart Journal | February 5, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.4111 Get It

Abstract Background Treatment with immune-checkpoint inhibitors (ICI) may be associated with adverse cardiac events. Troponin elevation is part of the diagnostic criteria for ICI related myocarditis (ICIrM) and myocardial infarction (MI), however there is limited data for causes of troponin elevation independent of MI and ICIrM and their clinical outcomes with ICI therapy. Purpose To assess the diagnostic and prognostic value of high-sensitivity troponin T (hs-TnT) in patients treated with ICI based on different etiologies and association with cardiac events. Methods All patients treated with ICI who had hs-TnT measured at a multi-center institution from 2011 to 2022 were included. Medical records were reviewed for baseline characteristics and long-term outcomes, including cardiac death and MACE (MI, stroke, heart failure [HF]), and cause of hs-TnT elevation. Risk of cardiac events and mortality were compared for the different etiologies of hs-TnT elevation. Results Of 5,423 patients treated with ICI, 1669 had post-ICI hs-TnT measurement. Mean age was 68.7±11.3 years, 58.3% were male, with follow-up through one year from ICI first administration. Elevated hs-TnT was seen in 1136 patients, with the different causes for elevation depicted in Figure 1, panel A. ICIrM patients exhibited the highest median hs-TnT value of 364 ng/L (IQR 1096), followed by a median of 98 ng/L for MI/Type 2 ischemia, 61 ng/L for infection/sepsis, 51 ng/L for pulmonary embolus, 50 ng/L for HF and 27 ng/L for indeterminate causes, Figure 1, panel B. Additionally, median time from first ICI dose to hs-TnT elevation according to each of the diagnoses are depicted in Figure 1, panel C, with ICIrM showing the shortest median time of 44 days (IQR 74). Hs-TnT elevation in patients with ICIrM had the highest risk for cardiac death (HR 52.7, 95% CI 11.7-238.0, p<0.001), followed by hs-TnT elevation due to HF (HR 15.9, 95% CI 2.9-87.0, p=0.001), MI/type 2 ischemia (HR 11.6, 95% CI 2.4-56.1, p=0.002), and infection/sepsis (HR 5.7, 95% CI 1.0-31.0, p=0.045) compared to those with no hs-TnT elevation, Figure 2, panel A. Similarly, patients with ICIrM had highest risk for MACE (HR 8.2, 95% CI 4.4-15.3, p<0.001), followed by increased hs-TnT due to MI/type 2 ischemia (HR 8.1, 95% CI 5.0-13.1, p<0.001), HF (HR 7.6, 95% CI 4.2-13.7, p<0.001), pulmonary embolism (HR 5.1, 95% CI 2.5-10.8, p<0.001), infection/sepsis (HR 4.1, 95% CI 2.4-7.0, p<0.001), and indeterminate cause (HR 2.4, 95% CI 1.5-3.8, p<0.001), Figure 2, panel B. Conclusions Hs-TnT measurements have prognostic value for cardiac events in cancer patients receiving ICI therapy, including in those without ICIrM. Patients with ICIrM demonstrated the highest median hs-TnT levels and the poorest outcomes, with a graded response observed; the worst prognosis was seen in patients with hs-TnT elevation due to ICIrM, followed by other causes, and those without hs-TnT elevation had the best prognosis.Figure 1 Figure 2
Ticagrelor vs. clopidogrel in elderly patients following acute myocardial infarction: a multicenter international analysis
Ibrahim, R, Tahsin, M T, Abdelnabi, M A, Pham, H P, Allam, M A, Perez, S P, Farina, J F, Tamarappoo, B T, Ayoub, C A, Lee, K L, Arsanjani, R A, Ibrahim, Ramzi , Tahsin, Malak , Abdelnabi, Mahmoud , Allam, Mohamed , Tamarappoo, B., Arsanjani, Reza

Mayo Clinic

European Heart Journal | February 5, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.1781 Get It

Abstract Background/Introduction Acute coronary syndrome (ACS) is common among elderly patients and is associated with a high risk of complications. Managing ACS, particularly dual antiplatelet therapy (DAPT), poses challenges due to the increased risk of recurrent hemorrhagic and ischemic events in this population. Purpose This study evaluated cardiovascular outcomes in patients ≥75 years that were initiated on DAPT with aspirin (ASA) plus either ticagrelor or clopidogrel following an acute myocardial infarction (AMI). Methods We used the TriNetX repository to identify adult patients (≥75 years) diagnosed with AMI between January 1, 2011, and December 31, 2021, who subsequently initiated DAPT and were not on anticoagulation. Patients were stratified into two cohorts: ASA + ticagrelor and ASA + clopidogrel. Outcomes assessed included major bleeding, repeat coronary intervention, all-cause mortality, all-cause hospitalizations, stroke, new-onset atrial fibrillation, and pacemaker implantation. Follow-up time was restricted to one year. A 1:1 propensity score matching algorithm was applied using the greedy nearest-neighbor method with a caliper of 0.1 pooled standard deviations to ensure balance (i.e., comorbidities, medications, laboratory values) between the two cohorts. Logistic regression models were used to calculate adjusted odds ratios (aOR), and Cox proportional hazards models estimated hazard ratios (HR). Results Before propensity score matching (PSM), 19,859 patients were in the ASA + ticagrelor cohort, and 47,032 were in the ASA + clopidogrel cohort. Post-PSM, 19,746 patients remained in each cohort, with a mean age of 82.2 years and a mean follow-up duration of 298.77 days for the ASA + ticagrelor cohort and 297.59 days for the ASA + clopidogrel cohort. The ASA + ticagrelor cohort had a higher incidence of major bleeding (aOR 1.19 [95% CI, 1.08–1.31]) and pacemaker implantation (aOR 1.14 [95% CI, 1.02–1.29]) compared to the ASA + clopidogrel cohort. Event-free survival analysis showed lower survival rates for major bleeding (HR 1.18 [95% CI, 1.07–1.30]) and pacemaker implantation (HR 1.14 [95% CI, 1.01–1.28]). No significant differences were observed between cohorts in repeat coronary interventions (aOR 0.95 [95% CI, 0.88–1.03]), atrial fibrillation (aOR 1.03 [95% CI, 0.97–1.08]), all-cause mortality (aOR 1.03 [95% CI, 0.96–1.12]), all-cause hospitalization (aOR 1.01 [95% CI, 0.97–1.05]), or stroke (aOR 0.95 [95% CI, 0.86–1.04]). Conclusions In elderly patients, DAPT with ASA + ticagrelor was associated with higher rates of major bleeding and need for pacemaker compared to ASA + clopidogrel. Given the similar risks of recurrent coronary intervention and mortality between the two regimens, these findings highlight the need for careful consideration when selecting ticagrelor over clopidogrel in this population.
Artificial Intelligence–Electrocardiography to Predict Incident Atrial Fibrillation and Clinical Outcomes in Kidney Transplant Recipients
Scalia, Isabel G., Farina, Juan M., Abdelnabi, Mahmoud H., Pietri, Milagros Pereyra, Ibrahim, Ramzi, Awad, Kamal, Abbas, Mohammed Tiseer , Ali, Nima Baba , Mahmoud, Ahmed K., Steidley, D. Eric, Masry, Hicham El , Sorajja, Dan , Scott, Luis R., Lee, Kwan, Johnson, D. W., Riad, Samy M. , Lester, Steven J., Jk, Oh, Ayoub, Chadi, Arsanjani, Reza, Farina, Juan M. , Ibrahim, Ramzi , Scalia, Isabel G. , Scalia, Isabel G , Farina, Juan M , Pereyra Pietri, Milagros, Pathangey, Girish , Ibrahim, Ramzi , Tiseer Abbas, Mohammed, Baba Ali, Nima , Alsidawi, Said , El Masry, Hicham , Sorajja, Dan , Scott, Luis R , Lee, Kwan S , Cho, Yeoungjee , Johnson, David W , Wadei, Hani M , Chao, Chieh-Ju , Mour, Girish K , Arsanjani, Reza , Abbas, Mohammed Tiseer , Pereyra, Milagros , Pathangey, Girish , Awad, Kamal , Mahmoud, Ahmed , Alsidawi, Said , Steidley, D. Eric , Scott, Luis R. , Cho, Yeoungjee , Wadei, Hani M. , Chao, Chieh‐Ju , Mour, Girish , Arsanjani, Reza

Mayo Clinic

Kidney360 | February 4, 2026 | Volume: 7 | Issue: 5 | Pages: 1128-1140

10.34067/kid.0000001063 | PMID 41637137 Get It

Key Points Atrial fibrillation after kidney transplantation is common and is associated with poor prognosis. Artificial intelligence applied to 12-lead electrocardiograms pretransplant accurately predicts the risk of new-onset atrial fibrillation in our cohort. High-risk artificial intelligence electrocardiography score was independently associated with increased risk of mortality and allograft failure. Background Incident atrial fibrillation (AF) is common after kidney transplantation (KTx) and is associated with worse clinical outcomes. Artificial intelligence electrocardiography (AI-ECG) algorithms have demonstrated efficacy in predicting risk of new-onset AF in the general population; however, their prognostic value in KTx recipients is relatively unknown. Methods Retrospective analysis was conducted on KTx recipients without AF, with at least one pretransplant ECG between 2011 and 2021 across three tertiary centers in the United States (Mayo Clinic sites in MN, AZ, and FL). A previously validated AI-ECG algorithm estimated the probability of incident AF for each patient. Based on AI-ECG probabilities, patients were categorized into high-risk and low-risk groups, with the optimal AI-ECG score cutoff determined. The incidence of new-onset AF, allograft failure, and mortality was compared between groups. Results Overall, 6246 patients (age 53.5±13.8 years; 58.9% male) were included. Pretransplant AI-ECG probability of AF ≥5% was the optimal cutoff for high risk of incident AF (sensitivity 72%, specificity 62%). High-risk scores were associated with true new-onset AF at 30 days (adjusted hazard ratio [aHR], 2.89; 95% confidence intervals [CI], 2.05 to 4.09; P < 0.001), 3 years (aHR, 2.54; 95% CI, 1.99 to 3.26, P < 0.001), and 5 years post-transplant (aHR, 2.48; 95% CI, 1.99 to 3.09, P < 0.001). High-risk AI-ECG scores were also associated with increased mortality (aHR, 1.56; 95% CI, 1.30 to 1.88, P < 0.001) and overall allograft failure (aHR, 1.50; 95% CI, 1.30 to 1.75, P < 0.001) through the 5-year follow-up. Conclusions This pretransplant AI-ECG parameter identified patients at increased risk of new-onset AF post-KTx and provided prognostic utility. Overall, this easy to obtain tool allows for risk stratification of patients who may benefit from closer monitoring, targeted risk factor modification, and early intervention.
Combination therapy with sglt2-inhibitors and tafamidis in transthyretin cardiomyopathy
Forst, B, Ibrahim, R, Chung, K, Pham, H N, Habib, Eiad, Farina, J, Lee, J Z, Ayoub, Chadi, Lee, K, Steidley, Eric, Sorajja, Dan , Rosenthal, J, Arsanjani, R, Forst, Beani, Pham, Hieu , Habib, Eiad , Lee, Justin Z. , Hilal, Talal , Arsanjani, Reza

Mayo Clinic

European Heart Journal | February 4, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.1223 Get It

Abstract Introduction/Background Transthyretin amyloidosis (ATTR) is a debilitating disease that leads to progressive cardiac dysfunction. Tafamidis is the gold standard therapy for ATTR cardiomyopathy. In recent observational studies, sodium-glucose cotransporter-2 inhibitors (SGLT2-Is) have demonstrated cardiovascular benefits in ATTR cardiomyopathy, but their role in ATTR cardiomyopathy as combination therapy with tafamidis remains unclear. Purpose To investigate the impact of combination therapy with tafamidis and SGLT2-Is versus just tafamidis in patients with known ATTR cardiomyopathy. Methods This retrospective cohort study utilized data from the TriNetX multinational database. Patients diagnosed with ATTR cardiomyopathy who received tafamidis were identified and stratified into two cohorts based on SGLT2-I use. Outcomes were assessed over three years, including all-cause mortality, all-cause hospitalizations, acute myocardial infarction (AMI), acute heart failure (HF) hospitalizations, ischemic stroke, atrial fibrillation/flutter, end-stage renal disease (ESRD) or requirement for renal replacement therapy, and ventricular tachycardia. Propensity score matching was used to balance both cohorts based on clinical comorbidities, medication use, and laboratory data. Adjusted odds ratios (OR) were calculated by logistic regression models. Results After propensity score matching, 409 patients were included in each cohort with a follow-up duration of 722 days (SD 320.87) for the SGLT2-I cohort and and 755.90 days (SD 363.26) for the non-SGLT2-I cohort. SGLT2-Is were associated with significantly lower rates of all-cause hospitalizations (41.1% vs. 50.9%; OR 0.67 [p = 0.005]) and AMI (6.6% vs. 13.9%, OR 0.44 [p = 0.001]), which persisted by three years (all-cause hospitalizations: 52.1% vs. 61.4%, OR 0.67 [p = 0.006] and myocardial infarction: 11.2% vs. 18.3%, OR 0.56 [p = 0.004]). No significant differences among the two cohorts were observed for all-cause mortality, acute HF hospitalizations, ischemic stroke, atrial fibrillation/flutter, ventricular tachycardia, or ESRD/need for renal replacement therapy. Conclusions SGLT2-Is, in combination with tafamidis, are associated with decreased all-cause hospitalizations and AMI in ATTR cardiomyopathy. While a mortality benefit was not demonstrated, these results depict the magnitude of clinical benefit derived from combination therapy with tafamidis and SGLT2-Is as opposed to prior observational studies which investigated SGLT2-I single therapy
Direct oral anticoagulants versus warfarin for atrial fibrillation in patients with transthyretin cardiac amyloidosis: a retrospective cohort analysis
Habib, Eiad, Ibrahim, R, Abdelnabi, M, Pham, N, Masry, H El, Rosenthal, J, Steidley, Eric, Scott, L, Sorajja, Dan , Ayoub, C, Arsanjani, R, Habib, Eiad , Abdelnabi, Mahmoud , Farina, Juan M. , Masry, Hicham El , Arsanjani, Reza

Mayo Clinic

European Heart Journal | February 4, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.509 Get It

Abstract Background/Introduction Patients with transthyretin cardiac amyloidosis (ATTR-CA) and atrial fibrillation (AF) have increased risk for left atrial thrombi, necessitating anticoagulation therapy if bleeding risk is not prohibitive. Limited data is available comparing the use of direct oral anticoagulants (DOACs) to warfarin in this population. Purpose To evaluate and compare clinical efficacy and safety outcomes of DOACs versus warfarin in patients with ATTR-CA and AF. Methods We conducted a retrospective cohort study using the TriNetX Network, which includes data from over 140 million patients, between 2014 and 2022. Adults (aged ≥18 years) with ATTR-CA and AF were identified. These patients were further categorized into two groups: one cohort which utilized DOACs for oral anticoagulation and the other cohort on warfarin. 1:1 propensity score matching (PSM) was utilized to balance baseline characteristics between the two cohorts. The primary outcome was rate of stroke, with secondary outcomes including all-cause death, all-cause hospitalizations, and acute heart failure exacerbations. Safety outcomes included intracranial hemorrhage, gastrointestinal hemorrhage, and hematuria. Adjusted odds ratios (aORs) with 95% confidence intervals (CIs) were calculated. Results Among 8,214 adults with ATTR-CA and AF, 5,774 patients were on a DOAC while 2,440 patients were on warfarin. After PSM, 2,425 patients were included in each group. The use of DOACs for AF in patients with ATTR-CA was associated with a significantly lower risk of ischemic stroke compared to warfarin (5.7% versus 7.3%, aOR 0.771 [95% CI, 0.612-0.971]) by the end of the one year follow up. There were no differences in all-cause mortality (19.8% versus 21%, aOR 0.927 [95% CI, 0.806-1.066]), all-cause hospitalizations (19.2% versus 21.6%, aOR 0.863 [95% CI, 0.624-1.195]) or heart failure exacerbations (43.6% versus 46%, aOR 0.906 [95% CI, 0.809-1.015]). Safety outcomes favored DOACs over warfarin, with a lower risk of intracranial hemorrhage (4.5% versus 7.8%, aOR 0.565 [95% CI, 0.444-0.720]), and comparable rates of GI hemorrhage and hematuria. Conclusions DOACs may be safely used in ATTR-CA patients with AF, offering a lower risk of stroke compared to warfarin and a more favorable safety profile. These findings emphasize the potential advantages of DOACs in this population and underline the need for prospective studies to validate these results.
Abstract WP127: Sex-Specific Differences in Presentation and Outcomes after Cervical Artery Dissection
Sidebottom, Christian, Omran, Setareh Salehi , Yaghi, Shadi, Shu, Ligi, Lee, Conner, Crandell, Ross, Lester, Evan, Henninger, Nils, Katheryna, Antonenko, Khan, Muhib, Mallick, Dania, Rothstein, Aaron, Khazaal, Ossama , Engelter, Stefan T, Traenka, Christopher , Gandhi, Preet , Metanis, Issa, Leker, Ronen, Renneberg, Regina Von, Guo, Xiaofan, Ghannam, Malik, AlMajali, Mohammad, Samaniego, Edgar A., Fonseca, Ana, Cruz, Diana , Romoli, Michele, Keser, Zafer, Marialuisa, Zedde, Bakradze, Ekaterina, Velez, Faddi Saleh, Penckofer, Mary , Siegler, J, Zubair, Adeel , Marto, Joao Pedro, Klein, Piers, Nguyen, Thanh N., Khasiyev, Farid, Elnazeir, Marwa , Elangovan, Cheran, Krishnaiah, Balaji , Henninger, Nils , Henninger, Nils , Muppa, Jayachandra , Gunduz, Muhammed Enes , Heldner, Mirjam R. , Nehme, Ahmad , Khan, Muhib , Rothstein, Aaron , Kaufmann, Josefin E. , Engelter, Stefan T. , Metanis, Issa , Leker, Ronen R , Shahripour, Reza Bavarsad , Ghannam, Malik , Samaniego, Edgar A , Cruz, Diana, Romoli, Michele , Keser, Zafer , Grory, Brian Mac , Bakradze, Ekaterina , Velez, Faddi G. Saleh , Siegler, James E. , Willey, Joshua , Marto, João Pedro , Klein, Piers , Nguyen, Thanh N. , Simpkins, Alexis N. , Elangovan, Cheran

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.wp127 Get It

Background and Objectives: Cervical artery dissection (CeAD) is a leading cause of ischemic stroke in younger adults, yet sex-specific variations in its clinical presentation, imaging characteristics, and outcomes remain underexplored. We aimed to evaluate these differences using data from a large, multicenter registry. Methods: We analyzed data from the STOP-CAD registry, which includes patients with radiologically confirmed non-traumatic CeAD enrolled between 2015 and 2021 across multiple centers. Clinical and imaging characteristics were compared between men and women using multivariable logistic regression. Outcomes assessed included ischemic stroke recurrence at 180 days, excellent functional outcome (modified Rankin Scale [mRS] 0–1) at 90 days, symptomatic intracerebral hemorrhage (sICH), and mortality. Results: Among 4,023 patients with CeAD, 1,783 (44.6%) were women. Compared to men, women were younger (median age: 42 vs 50 years), more likely to have a history of migraine (26.9% vs 8.3%) and connective tissue disorders (14.3% vs 5.8%), and presented more frequently with non-ischemic symptoms such as headache, neck pain, or tinnitus (adjusted OR [aOR] 2.0; 95% CI, 1.8–2.3; p<0.001). Women had significantly higher odds of vertebral artery dissection (OR, 1.3; 95% CI, 1.2-1.5; p<0.001), multivessel involvement (OR, 2.1; 95% CI, 1.7-2.5; p<0.001), and pseudoaneurysm formation (OR, 1.3; 95% CI, 1.1-1.6; p=0.003). Despite these differences, there was no significant sex-based difference in key clinical outcomes: excellent functional recovery at 90 days (OR 0.94; 95% CI 0.76-1.15 p=0.542), ischemic stroke recurrence at 180 days (OR 0.56 CI 0.23-1.3 p=0.213), or mortality (OR 0.83; 95% CI 0.47-1.48, p=0.529). Conclusion: In this large international cohort, we observed women with CeAD were younger, more likely to present with non-ischemic symptoms with distinct imaging features. These underscore the need for heightened clinical suspicion of CeAD in women presenting with atypical symptoms, even in the absence of ischemic deficits or conventional vascular risk factors, and suggest that sex-specific phenotyping may enhance diagnostic accuracy and early management.
Abstract DP029: Incidence, risk factors, aneurysm growth, and outcomes of cervical artery dissection patients with dissecting aneurysm: STOP-CAD subanalysis
Khan, Muhib, Keser, Zafer, Nguyen, Thanh N., Lee, Elizabeth M., Ho, Melanie, Shu, Liqi , Klein, Piers, Mallick, Dania, Griffin, Kim, Mandel, Daniel M, Leker, Ronen, Metanis, Issa, Krishnaiah, Balaji , Omran, Setareh Salehi , Bakradze, Ekaterina, Henninger, Nils, Engelter, Stefan T, Katheryna, Antonenko, Marto, Joao Pedro, Rothstein, Aaron, Khazaal, Ossama , Nolte, Christian H., Crandall, Ross , Lester, Evan, MacGrory, Brian, Ghannam, Malik, AlMajali, Mohammad, Zubair, Adeel , Elnazeir, Marwa , Kasab, Sami Al, Asad, Syed Daniyal , Balabhadra, Anvesh , Cruz, Diana García, Romoli, Michele, Velez, Faddi Saleh, Sen, Shayak, Zedde, Marialuisa, Samaniego, Edgar, Stretz, Christoph, Kam, Wayneho , AbdalKader, Mohamad, Yaghi, Shadi, Henninger, Nils , Henninger, Nils , Khan, Muhib , Keser, Zafer , Klein, Piers , Leker, Ronen R , Metanis, Issa , Shahripour, Reza Bavarsad , Bakradze, Ekaterina , Engelter, Stefan T. , Heldner, Mirjam R. , Siegler, James E. , Marto, João Pedro , Rothstein, Aaron , Nolte, Christian H. , Nehme, Ahmad , Ghannam, Malik , Kasab, Sami Al , Fonseca, Ana Catarina , Cruz, Diana, Romoli, Michele , Velez, Faddi G. Saleh , Simpkins, Alexis N. , Zedde, Marialuisa , Stretz, Christoph , Abdalkader, Mohamad , Yaghi, Shadi

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.dp029 Get It

Background: Cervical artery dissection (CeAD) accounts for nearly 25% of all ischemic strokes in young adults. CeAD can lead to the development of dissecting aneurysms (DA). However, the incidence, risk factors and outcomes of CeAD patients with DA is not well established. This study aims to identify risk factors for developing DA, subsequent growth, and impact on patient outcomes. Methods: This is a secondary analysis of the Antithrombotics for Stroke Prevention in Cervical Artery Dissection (STOP-CAD), a multicenter cross-sectional international retrospective study. CeAD patients were stratified for the presence of DA. We used multivariable regression to identify factors associated with DA. Patients with DA were further analyzed for DA growth. The primary outcome was ischemic stroke after CeAD+DA diagnosis. Secondary outcomes included ischemic stroke after CeAD+DA with DA growth. Multivariable logistic regression analysis was used to assess the association between DA and risk factors. We also performed univariate Cox regression and generated Kaplan-Meier survival curves comparing study outcomes based on presence of DA and subsequent growth. Results: Of the 4023 patients included in the STOP-CAD study, 4008 were included in this analysis and 767 (19%) patients had DA (546 with DA on initial presentation). Patients with DA had a mean age of 46 [IQR 37-55] years and 50% (383) were women. In combined adjusted analyses, DA patients were more often non-Hispanic (aOR 0.63, 95% CI 0.41-0.94, p<0.02), more commonly had a history of migraine (aOR 1.27, 95% CI 1.01-1.59, p=0.037), connective tissue disorder (aOR 2.02, 95% CI 1.22-3.36, p=0.007), minor neck trauma (aOR 1.70, 95% CI 1.29-2.26, p<0.001) and were more likely to present with ischemic stroke (aOR 1.73, 95% CI 1.05-2.87, p=0.031). DA growth was noted in 55 out of 546 (10%) patients with DA on presentation. There was no significant difference in the risk of ischemic stroke by day 180 in patients with DA (hazard ratio [HR] 0.92 [95% CI, 0.65-1.30]; P =0.63) or DA growth (HR 2.40, [95% CI, 0.79-7.24]; P =0.12). Conclusion: In this subanalysis of STOP-CAD, nearly one in five patients with CeAD developed a DA. Factors associated with a higher likelihood of DA included non-Hispanic ethnicity, history of migraine, connective tissue disorder, minor neck trauma, and ischemic stroke at presentation. DA diagnosis and DA growth did not impact the risk of subsequent ischemic stroke at 6 months.
Abstract A048: De Novo Pseudoaneurysm Formation After Cervical Artery Dissection: Incidence, Risk Factors, and Outcomes
Keser, Zafer, Khan, Muhib, Nguyen, Thanh N., Lee, Elizabeth M., Shu, Liqi , Ho, Melanie, Klein, Piers, Mallick, Dania, Griffin, Kim, Mandel, Daniel M, Leker, Ronen, Metanis, Issa, Krishnaiah, Balaji , Omran, Setareh Salehi , Bakradze, Ekaterina, Henninger, Nils, Engelter, Stefan T, Marto, Joao Pedro, Rothstein, Aaron, Khazaal, Ossama , Nolte, Christian H., Crandall, Ross , Lester, Evan, AlMajali, Mohammad, Ghannam, Malik, Zubair, Adeel , Elnazeir, Marwa , Kasab, Sami Al, Asad, Syed Daniyal , Balabhadra, Anvesh , Romoli, Michele, Cruz, Diana, Velez, Faddi Saleh, Sen, Shayak, Marialuisa, Zedde, Samaniego, Edgar A., Stretz, Christoph, Kam, Wayneho , AbdalKader, Mohamad, Yaghi, Shadi, Henninger, Nils , Henninger, Nils , Keser, Zafer , Khan, Muhib , Ho, Melanie, Klein, Piers , Leker, Ronen R , Metanis, Issa , Shahripour, Reza Bavarsad , Bakradze, Ekaterina , Engelter, Stefan T. , Heldner, Mirjam R. , Antonenko, Kateryna , Siegler, James E. , Marto, João Pedro , Rothstein, Aaron , Nolte, Christian H. , Nehme, Ahmad , Grory, Brian Mac , Ghannam, Malik , Kasab, Sami Al , Fonseca, Ana Catarina , Romoli, Michele , Cruz, Diana , Velez, Faddi G. Saleh , Simpkins, Alexis N. , Samaniego, Edgar A , Stretz, Christoph , Abdalkader, Mohamad , Yaghi, Shadi

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.a048 Get It

Background: The clinical characteristics and complications associated with de novo pseudoaneurysm formation beyond the acute phase of cervical artery dissection remain poorly defined. In this study, we examined the incidence, risk factors, and related ischemic and hemorrhagic events of post-acute de novo pseudoaneurysm formation. Methods: We analyzed data from the STOP-CAD study (Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection). A de novo pseudoaneurysm was defined as a new (not present on initial imaging) focal enlargement in the diameter of the artery, greater than the native lumen. The incidence of de novo pseudoaneurysm was assessed at 90 days, 180 days, and beyond 180 days of follow-up. Univariate and multivariate regression analyses were conducted to identify risk factors for post-acute de novo pseudoaneurysm formation. Kaplan-Meier survival estimates were used to compare ischemic and hemorrhagic events between patients with and without de novo pseudoaneurysms. Results: Among 4008 patients, 546 were excluded as they had dissecting pseudoaneursyms on initial presentation. Therefore, 3,462 patients were included in this analysis of whom 220 patients (6.35%) developed a de novo pseudoaneurysm over a maximum follow-up of 4.4 years. Of these, 127 (57.72%) were detected within the first 90 days, and 172 (78.18%) within the first 180 days. In multivariate regression analyses, in addition to hypertension, active smoking and Hispanic ethnicity, fibromuscular dysplasia (FMD) was an independent risk factor for post-acute de novo pseudoaneurysm formation (adjusted OR: 2.160; 95% CI: 1.408–3.315; p < 0.001). Notably, the presence of a de novo pseudoaneurysm was not associated with a significant increase in ischemic (hazard ratio [HR] 1.43 [95% CI, 0.89–2.30]; P=0.14) or hemorrhagic events (hazard ratio [HR] 1.42 [95% CI, 0.43–4.69]; P=0.57). Conclusion: De novo pseudoaneurysm formation following a diagnosis of a cervical artery dissection is not uncommon and most frequently occurs within the first 180 days. FMD was independently associated with this complication. The development of a de novo pseudoaneurysm did not significantly increase the risk of subsequent ischemic or hemorrhagic events.
Abstract A034: Outcomes of Patent Foramen Ovale Closure in Patients Over 60 Years with Cryptogenic Stroke: A Systematic Review and Meta-Analysis
Phan, Cattien , Ghozy, Sherief, Ravichandran, Soumya , Maleki, Ana H., Dumitrascu, Oana, Agrawal, Kush , Modir, Royya , Hemmen, Thomas, Poli, Sven, Zuern, Christine S., Trabattoni, Daniela, Meyer, Brett C. , Jazayeri, Seyed Behnam , Ghozy, Sherief , Hemmen, Thomas , Poli, Sven , Zuern, Christine S. , Trabattoni, Daniela , Meyer, Dawn , Shahripour, Reza Bavarsad

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.a034 Get It

Background: In younger patients (<60 years) with cryptogenic stroke presumed to be patent foramen ovale (PFO)-related, the standard approach involves transcatheter PFO closure combined with antithrombotic therapy (ATA). However, due to their exclusion from randomized clinical trials, no formal recommendations exist for patients ≥60 years. This study investigates whether PFO closure benefits patients ≥60 years with prior cryptogenic stroke or if ATA remains the preferred option. Methods: We searched the PubMed, Embase, Web of Science, and ScienceDirect databases to obtain articles in all languages from January 2004 until July 2025. The primary outcome was a risk of recurrent stroke during follow-up and secondary outcomes were risk of new-onset atrial fibrillation (AF), all-cause mortality and in-hospital complications. PROSPERO registration ID: CRD420250652870. Results: One post hoc evaluation of the DEFENSE-PFO trial and eleven observational studies were included. Compared to ATA, PFO closure was associated with a reduced risk of recurrent stroke (HR=0.60; 95% CI: 0.45 to 0.80, p<.001) and mortality (HR=0.41; 95% CI: 0.19 to 0.90, p=.02; I2 = 43.8%) with no difference in risk of new-onset AF (HR=1.13, 95%CI: 0.53 to 2.44, p=.74). When compared with patients <60 years, individuals ≥60 years had a higher risk of recurrent stroke (HR = 2.68; 95% CI 1.40–5.13; p=.002), new-onset AF (HR = 4.12; 95% CI 1.90–8.95; p<0.001) and mortality during follow-up (HR = 8.24; 95% CI 3.49–19.46; p<.0001). In-hospital complications after PFO closure were comparable between two age groups. Conclusion: While PFO closure may reduce ischemic stroke risk in older patients with cryptogenic stroke, this benefit is offset by higher absolute risks for recurrent stroke, new-onset AF, and mortality. Therefore, highly individualized patient selection and age-specific risk tools are crucial. Further long-term randomized trials are essential to optimize PFO closure in this population.